PT2678679T - Utilização de tubulina acetilada como um biomarcador da resposta farmacológica a furazanobenzimidazolos - Google Patents

Utilização de tubulina acetilada como um biomarcador da resposta farmacológica a furazanobenzimidazolos

Info

Publication number
PT2678679T
PT2678679T PT127048262T PT12704826T PT2678679T PT 2678679 T PT2678679 T PT 2678679T PT 127048262 T PT127048262 T PT 127048262T PT 12704826 T PT12704826 T PT 12704826T PT 2678679 T PT2678679 T PT 2678679T
Authority
PT
Portugal
Prior art keywords
furazanobenzimidazoles
biomarker
drug response
acetylated tubulin
tubulin
Prior art date
Application number
PT127048262T
Other languages
English (en)
Inventor
Alexandra Lane Heidi
Bachmann Felix
Original Assignee
Basilea Pharmaceutica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica Ag filed Critical Basilea Pharmaceutica Ag
Publication of PT2678679T publication Critical patent/PT2678679T/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/44Multiple drug resistance
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PT127048262T 2011-02-24 2012-02-21 Utilização de tubulina acetilada como um biomarcador da resposta farmacológica a furazanobenzimidazolos PT2678679T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11155774 2011-02-24

Publications (1)

Publication Number Publication Date
PT2678679T true PT2678679T (pt) 2017-04-07

Family

ID=44065555

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127048262T PT2678679T (pt) 2011-02-24 2012-02-21 Utilização de tubulina acetilada como um biomarcador da resposta farmacológica a furazanobenzimidazolos

Country Status (14)

Country Link
US (2) US9476889B2 (pt)
EP (1) EP2678679B1 (pt)
JP (1) JP6295081B2 (pt)
CN (1) CN103392130B (pt)
AU (1) AU2012219611C1 (pt)
CA (1) CA2824497A1 (pt)
DK (1) DK2678679T3 (pt)
ES (1) ES2621413T3 (pt)
HK (1) HK1191096A1 (pt)
HU (1) HUE032187T2 (pt)
PL (1) PL2678679T3 (pt)
PT (1) PT2678679T (pt)
WO (1) WO2012113802A1 (pt)
ZA (1) ZA201306086B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2691533B1 (en) * 2011-03-29 2017-04-05 Basilea Pharmaceutica AG Use of phospho-akt as a biomarker of drug response
US10392920B2 (en) * 2013-12-05 2019-08-27 Schlumberger Technology Corporation Method and system of quantitative cement evaluation using logging while drilling
WO2015132931A1 (ja) * 2014-03-06 2015-09-11 三菱重工業株式会社 電動移動体情報提供装置と電動移動体情報提供方法
EP3365680A1 (en) 2015-10-22 2018-08-29 Basilea Pharmaceutica International AG Use of eb1 as a biomarker of drug response
KR102648947B1 (ko) 2017-04-26 2024-03-18 바실리어 파마슈티카 인터내셔널 리미티드 푸라자노벤즈이미다졸 및 이의 결정 형태의 제조 공정
EP3624790A1 (en) 2017-05-16 2020-03-25 Basilea Pharmaceutica International AG Novel dosage principle for drugs useful for treating neoplastic diseases
EP3713565A1 (en) * 2017-11-20 2020-09-30 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
CN109053584B (zh) * 2018-09-12 2022-03-18 南京大学 一类1,2-二芳基苯并咪唑衍生物的制备及其应用
WO2020058405A1 (en) * 2018-09-20 2020-03-26 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
KR102503593B1 (ko) * 2020-03-11 2023-02-24 연세대학교 산학협력단 항암제 내성 진단 또는 치료용 조성물
CN114902047A (zh) * 2020-03-16 2022-08-12 株式会社漫丹 T细胞淋巴瘤的指标的检测方法及其应用
WO2022053549A1 (en) 2020-09-10 2022-03-17 Basilea Pharmaceutica International AG Use of c-myc as a biomarker of drug response
WO2024010479A1 (en) * 2022-07-06 2024-01-11 I3S - Instituto De Investigação E Inovação Em Saúde, Associação Tubulin acetylation and its associated post-translational modifications as biomarkers of response to treatment with taxol, taxanes and other microtubule stabilizing anti-cancer agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030095953A1 (en) * 1999-11-12 2003-05-22 Myles C. Cabot Methods of reversing drug resistance in cancer cells
US20050227300A1 (en) * 2001-12-07 2005-10-13 Atadja Peter W Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
WO2004103994A1 (en) 2003-05-23 2004-12-02 Basilea Pharmaceutica Ag Furazanobenzimidazoles
WO2006102557A2 (en) * 2005-03-22 2006-09-28 The President And Fellows Of Harvard College Treatment of protein degradation disorders
EP2644199B1 (en) * 2007-03-05 2017-10-11 NewSouth Innovations Pty Limited Methods for detecting and modulating the sensitivity of tumour cells to anti-mitotic agents
KR20100072024A (ko) * 2007-09-14 2010-06-29 메틸진 인크. 히스톤 탈아세틸화 효소 hdac1, hdac2 및/또는 hdac3의 선택적 억제제 및 미세관 안정화제로의 암 병용 치료법
EP2459553B1 (en) * 2009-07-27 2014-10-01 Basilea Pharmaceutica AG Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases

Also Published As

Publication number Publication date
US9476889B2 (en) 2016-10-25
AU2012219611A1 (en) 2013-07-25
CN103392130A (zh) 2013-11-13
CN103392130B (zh) 2015-11-25
ZA201306086B (en) 2014-04-30
US20140005237A1 (en) 2014-01-02
US10067120B2 (en) 2018-09-04
AU2012219611B2 (en) 2016-03-03
NZ613022A (en) 2015-11-27
PL2678679T3 (pl) 2017-07-31
WO2012113802A1 (en) 2012-08-30
JP2014511486A (ja) 2014-05-15
DK2678679T3 (en) 2017-04-24
ES2621413T3 (es) 2017-07-04
HK1191096A1 (zh) 2014-07-18
US20170122934A1 (en) 2017-05-04
CA2824497A1 (en) 2012-08-30
JP6295081B2 (ja) 2018-03-14
HUE032187T2 (en) 2017-09-28
AU2012219611C1 (en) 2016-07-21
EP2678679B1 (en) 2017-02-08
EP2678679A1 (en) 2014-01-01

Similar Documents

Publication Publication Date Title
HK1191096A1 (zh) 乙酰化微管蛋白作為對呋咱並苯並咪唑類的藥物反應的生物標誌物的用途
HK1210180A1 (en) Derivatives of betulin
GB201104096D0 (en) Production of graphene
HK1204604A1 (en) Stereoselective total synthesis of noribogaine
HK1192323A1 (zh) -微管蛋白作為對呋咱並苯並咪唑類的藥物反應的生物標誌物的用途
HK1189056A1 (zh) 作為藥物對呋咱並苯並咪唑響應的生物標記的用途
ZA201306520B (en) Use of phospho-akt as a biomarker of drug response
HK1185947A1 (zh) 作為呋咱並苯並咪唑類藥物應答的生物標記的用途
EP2776586A4 (en) BIOMARKERS OF REACTION ON PROTEASOMAL INHIBITORS
HK1203355A1 (en) Uses of 4-desferrithiocin analogs 4-
ZA201400248B (en) Synthesis of cleistainthin a and derivatives thereof
SG2014011639A (en) Measuring form changes of a substrate
PL2465868T3 (pl) Ulepszenie produkcji lipidów
GB201002606D0 (en) Production of fuels
EP2776043A4 (en) BIOMARKERS OF REACTION ON PROTEASOMAL INHIBITORS
GB2488866B (en) Use of GPS to detect repetitive motion
EP2684869A4 (en) PREPARATION OF 3-MERCAPOTOPROPIONATES
EP2782902A4 (en) DERIVATIVES FROM PHENOXYISOBUTTERIC ACID
EP2791349A4 (en) SYNTHESIS OF N-ACETYL-D-NEURAMIC ACID
EP2702991A4 (en) COMPOSITION OF ENTACOPONE
ZA201207838B (en) Use of zirconium or of a zirconium-comprising mixture
GB201106098D0 (en) Production of fuels
EP2663185A4 (en) FESTIVE FIGHTING POTENTIAL OF CALEBIN A
TWM433471U (en) Assembly structure of gear
GB201110310D0 (en) Paperless point of sale